Credit Suisse Group set a $121.00 target price on Eli Lilly And Co (NYSE:LLY) in a report published on Friday morning. The brokerage currently has a hold rating on the stock.

Other analysts have also issued reports about the stock. Citigroup set a $124.00 price target on shares of Eli Lilly And Co and gave the stock a hold rating in a research report on Tuesday, February 26th. Zacks Investment Research raised shares of Eli Lilly And Co from a hold rating to a buy rating and set a $121.00 price target on the stock in a research report on Wednesday, December 19th. Cantor Fitzgerald reaffirmed a buy rating on shares of Eli Lilly And Co in a research report on Monday, February 4th. Argus reaffirmed a buy rating on shares of Eli Lilly And Co in a research report on Thursday, December 27th. Finally, UBS Group began coverage on shares of Eli Lilly And Co in a research report on Wednesday, March 20th. They issued a buy rating and a $74.51 price objective on the stock. Ten research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. Eli Lilly And Co currently has an average rating of Buy and an average price target of $115.68.

NYSE LLY opened at $128.30 on Friday. The company has a debt-to-equity ratio of 1.07, a quick ratio of 1.38 and a current ratio of 1.73. Eli Lilly And Co has a 1 year low of $74.51 and a 1 year high of $130.75. The firm has a market cap of $132.84 billion, a price-to-earnings ratio of 23.12, a PEG ratio of 2.58 and a beta of 0.33.

Eli Lilly And Co (NYSE:LLY) last posted its quarterly earnings results on Wednesday, February 6th. The company reported $1.33 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.36 by ($0.03). Eli Lilly And Co had a return on equity of 44.66% and a net margin of 13.16%. The firm had revenue of $6.44 billion for the quarter, compared to the consensus estimate of $6.28 billion. During the same period last year, the company posted $1.14 earnings per share. The business’s revenue was up 4.5% compared to the same quarter last year. Equities research analysts anticipate that Eli Lilly And Co will post 5.66 EPS for the current year.

In related news, SVP Alfonso G. Zulueta sold 4,000 shares of the company’s stock in a transaction dated Thursday, January 31st. The shares were sold at an average price of $120.00, for a total value of $480,000.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Donald A. Zakrowski sold 1,000 shares of the company’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $127.01, for a total transaction of $127,010.00. The disclosure for this sale can be found here. Insiders sold 834,190 shares of company stock worth $102,516,602 over the last three months. Insiders own 0.11% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the stock. FDx Advisors Inc. grew its stake in shares of Eli Lilly And Co by 48.3% in the fourth quarter. FDx Advisors Inc. now owns 19,504 shares of the company’s stock valued at $2,257,000 after acquiring an additional 6,356 shares in the last quarter. State of Alaska Department of Revenue grew its stake in shares of Eli Lilly And Co by 3.3% in the fourth quarter. State of Alaska Department of Revenue now owns 204,487 shares of the company’s stock valued at $23,660,000 after acquiring an additional 6,474 shares in the last quarter. Waverton Investment Management Ltd grew its stake in shares of Eli Lilly And Co by 1.9% in the fourth quarter. Waverton Investment Management Ltd now owns 12,724 shares of the company’s stock valued at $1,472,000 after acquiring an additional 238 shares in the last quarter. Pennsylvania Trust Co grew its stake in shares of Eli Lilly And Co by 46.4% in the fourth quarter. Pennsylvania Trust Co now owns 85,021 shares of the company’s stock valued at $9,839,000 after acquiring an additional 26,947 shares in the last quarter. Finally, Sumitomo Life Insurance Co. grew its stake in shares of Eli Lilly And Co by 2.7% in the fourth quarter. Sumitomo Life Insurance Co. now owns 30,683 shares of the company’s stock valued at $3,551,000 after acquiring an additional 800 shares in the last quarter. Institutional investors and hedge funds own 78.69% of the company’s stock.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Article: What is Considered a Good Return on Equity (ROE)?

Analyst Recommendations for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.